Drug intelligence / Profile preview

HR18042

Development stage: Phase 2
Lead developer: Jiangsu Hengrui Medicine
Modality: Small Molecules
Administration: Oral

Overview

HR18042 is an investigational small molecule drug developed for the management of moderate to severe acute pain, particularly postoperative pain. It is being evaluated as an oral agent and has reached Phase 2 clinical trials for postoperative analgesia after impacted teeth removal surgery. The drug is classified as a COX-2 inhibitor, suggesting its mechanism involves selective inhibition of the cyclooxygenase-2 enzyme, which plays a key role in inflammation and pain signaling pathways. The developer of HR18042 is Jiangsu Hengrui Medicine.

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on HR18042.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HR18042.

Explore the full profile